Articles

The Latest in Testosterone Replacement Therapy

Karen Nash is a medical reporter and media consultant based in Monroeville, PA.

"I prefer doing transvaginal prolapse surgery with native tissue and always have. So I was not affected when mesh was restricted," says one urologist.

How has the FDA’s mesh guidance affected POP treatment?

In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.

Dr. Lemack on treatments in development for OAB

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

The benefits of holmium laser enucleation of the prostate with MOSES-enabled pulsed laser modulation justify its consideration as the gold standard surgical treatment for lower urinary tract symptoms related to benign prostatic hyperplasia, according to Amy E. Krambeck, MD.

MOSES-enabled pulsed laser allows same-day discharge without catheter

Patients using anticholinergic medications for the management of overactive bladder (OAB) are at increased risk of new-onset dementia compared with individuals treated with the beta-3 agonist mirabegron (Myrbetriq), according to findings of a new population-based, retrospective study published online March 13, 2020, in BJU International.

Study adds to evidence linking anticholinergics, dementia

"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.

New developments may change treatment of OAB

Unhealthy eating, like that associated with the Western diet, is associated with notably worse semen quality and less favorable testicular function than healthier eating patterns, according to a study of nearly 3,000 young Danish men published in JAMA Network Open (2020; 3:e1921610).

Unhealthy diet associated with poor semen quality

The FDA has accepted for review Urovant Sciences’ New Drug Application for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

FDA accepts new drug application for overactive bladder agent

Kerr is group content director for Urology Times.

AUA 2020 annual meeting canceled

A significant trend is occurring in the management of urethral stricture, with increased utilization of urethroplasty and decreased utilization of repeat endoscopic procedures, researchers at the University of Washington in Seattle report.

Study: Urethroplasty use on the rise

A study of kidney stone patients who were treated using ureteral access sheaths found no evidence of ureteral strictures an average of 4 years following ureteroscopy.

Sheath use not linked with strictures

Results of a randomized controlled clinical trial provide a rationale for urologists to integrate behavioral treatments into their practice for managing men with lower urinary tract symptoms of overactive bladder, according to the study’s authors.

Trial supports combined behavioral, medical approach to treating OAB

“If the long-term results prove to be as positive as the short-term results, then this could provide an intermediate option for patients with recurrent bulbar urethral strictures," says Sean P. Elliott, MD, MS.

Drug-coated balloon found efficacious for strictures

A new tool for kidney stone ablation demonstrates strong potential to dust and fragment stones more quickly and efficiently than devices currently available in the United States. However, clinical studies must be performed before this technology can be used during lithotripsy nationally.

Novel thulium laser fiber appears to outperform Holmium:YAG laser

Two pharmaceuticals in late-stage development may offer new therapeutic options for patients with rare forms of hyperoxaluria.

New agents may offer hope for two forms of hyperoxaluria

“Although the raw number of augmentations and diversions have been relatively unchanged, the proportion of patients undergoing both surgeries declined while the proportion of patients undergoing Botox injections doubled over the past 5 years,” said Rita P. Jen, MD, MPH.

OnabotA use on the rise for neurogenic bladder

"This work is important to our field, because it represents an effort to personalize treatment approaches to particular patients’ needs," writes Brian R. Matlaga, MD, MPH.

Study of stone pain stresses personalized treatment

Patients with kidney stones who rank their pain at the maximum level on a 100-point scale or whose number-one goal for treatment is to relieve pain are less likely to reach their treatment goals than other patients undergoing kidney stone treatment, a recent study found.

Pain-focused stone patients less likely to reach treatment goals

November 2019 proved to be a fruitful month for urology-specific FDA approvals, with the agency giving the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.

FDA approves new drug for UTI, two devices for OAB/incontinence

It may be time to take a closer look at antibiotic prophylaxis prior to ureteral stent removal, according to new data reported at the AUA annual meeting in Chicago.

All News